/Investor DB

Illumina Ventures — 2025 Investments

2 investments dated 2025 · listed companies and verified rows first · show all

Heptahepta.bioinNov 2025 · $6.7M

Hepta develops LiquidTransformer, an AI platform for analyzing cell-free DNA fragments in blood to detect chronic disease molecular signals.

AI & Machine LearningBiotechHealthtechSan Francisco, US

Hamed Amini(Founder)inSoheil Damangir(Founder)in

Co-investorsAlumni VenturesAME Cloud VenturesFelicis VenturesSeaX Ventures

Syntaxsyntax-bio.cominDec 2025

Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation.

BiotechDeep TechMedical DevicesChicago, US

Ryan Clarke(Co-Founder, Chief Scientific Officer)inNiko Balanis, PhD(Co-Founder, Chief Technology Officer)inBrad Merrill, PhD(Co-Founder, Head of Innovation)Matt MacDougall, MD, PhD(Scientific Cofounder, Immunology Physician, Stanford University)inPatrick Shaddow(Executive Officer, Director)John Craighead, PhD(Chief Executive Officer)

Co-investorsAstellas Venture Management LLCDCVC (Data Collective)DCVC BioDraper AssociatesLong GamePortal Innovations+1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.